Figures & data
Table 1 Clinical characteristics of 95 patients with NSCLC
Table 2 Peripheral blood analyses before and after 4 cycles of nivolumab therapy in NSCLC patients with or without combined COPD
Table 3 Pulmonary function tests before and after 4 cycles of nivolumab therapy in NSCLC patients with or without combined COPD
Table 4 Adverse events during the nivolumab therapy
Figure 2 FeNO levels before and after four cycles of nivolumab treatment. (A) FeNO levels before (filled circle) and after (unfilled circle) 4 cycles of nivolumab treatment. (B) Differences in FeNO levels before and after 4 cycles of nivolumab.
![Figure 2 FeNO levels before and after four cycles of nivolumab treatment. (A) FeNO levels before (filled circle) and after (unfilled circle) 4 cycles of nivolumab treatment. (B) Differences in FeNO levels before and after 4 cycles of nivolumab.](/cms/asset/dd855df5-fc5a-4d9d-b263-216ff255e13b/dcop_a_214610_f0002_c.jpg)
Figure 3 FeNO levels before and after four cycles of nivolumab treatment in patients with or without comorbid COPD. (A) FeNO levels before (filled circle) and after (unfilled circle) 4 cycles of nivolumab treatment in COPD and non-COPD patients. (B) Differences in FeNO levels before and after 4 cycles of nivolumab in COPD and non-COPD patients.
![Figure 3 FeNO levels before and after four cycles of nivolumab treatment in patients with or without comorbid COPD. (A) FeNO levels before (filled circle) and after (unfilled circle) 4 cycles of nivolumab treatment in COPD and non-COPD patients. (B) Differences in FeNO levels before and after 4 cycles of nivolumab in COPD and non-COPD patients.](/cms/asset/b3b9e1b2-64af-49dc-a382-19060fe9a842/dcop_a_214610_f0003_c.jpg)